# Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant

> **NCT06337331** · PHASE2 · WITHDRAWN · sponsor: **Northside Hospital, Inc.**

## Conditions studied

- Acute Myeloid Leukemia
- Myelodysplastic Syndromes

## Interventions

- **DRUG:** Venetoclax
- **DRUG:** Decitabine
- **DRUG:** Fludarabine
- **DRUG:** Busulfan
- **RADIATION:** Total Body Irradiation

## Key facts

- **NCT ID:** NCT06337331
- **Lead sponsor:** Northside Hospital, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-08-31
- **Primary completion:** 2026-08-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Unable to accommodate FDA recommendations for protocol revisions
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06337331

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06337331, "Adding Venetoclax to the High-dose Chemotherapy Regimen Prior to Mismatche Allogeneic Stem Cell Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06337331. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*